Churchill Capital Corp XIV

What the company does

No publishable business summary is available from the effective-prospectus read.

Use of proceeds

The company states that approximately $1,000,000 of net proceeds not held in the trust account will be used for expenses related to seeking and completing an initial business combination, regulatory reporting, office space and administrative support, and director and officer liability insurance, with the balance used as working capital. It also states that $300.0 million of proceeds, or $345.0 million if the over-allotment option is exercised in full, will be placed in a U.S.-based trust account.

Underwriters

The completed effective-prospectus read stated no underwriters.

Extracted from S-1 0001213900-26-115921, filed Nov 4, 2026 and verified against that filing text.

Key risk factors

• Redemption limitation

  “However, we would not be restricting our shareholders’ ability to vote all of their shares (including all shares held by those shareholders that hold more than 15% of the shares sold in this offering) for or against our initial business combination.”

• Warrant dilution

  “Our public shareholders may experience material dilution from the exercise of the private placement warrants contained in the private placement units to be purchased by our sponsor simultaneously with the closing of this offering, as well as from the conversion of any working capital loans into private placement units, if elected by the sponsor.”

• Founder-share dilution

  “Because our sponsor acquired the Class B ordinary shares at a nominal price of $.002 per share, our public shareholders will incur an immediate and substantial dilution upon the closing of this offering.”

• Anti-dilution issuance

  “In the case that additional Class A ordinary shares, or equity-linked securities (as described herein), are issued or deemed issued in excess of the amounts issued in this offering and related to the closing of our initial business combination, the ra”

• Management conflicts

  “As more fully discussed in “Management — Conflicts of Interest” on page 161, each of our officers and directors presently has, and any of them in the future may have additional, fiduciary, contractual or other obligations or duties to one or more other entities pursuant to which such officer or director is or will be required to present a business combination opportunity to such entities.”

• Sponsor profit incentive

  “The low price that our sponsor, executive officers and directors (directly or indirectly) paid for the founder shares creates an incentive whereby our officers and directors could potentially make a substantial profit even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders.”

• Worthless securities risk

  “If we are unable to complete our initial business combination within 24 months from the closing of this offering (or 27 months from the closing of this offering if we have executed a letter of intent, agreement in principle or definitive agreement for an initial business combination within 24 months from the closing of this offering), or by such earlier liquidation date as our board of directors may approve, and do not hold a shareholder vote to amend our amended and restated memorandum and articles of association to extend the amount of time we will have to consummate an initial business combination, the founder shares and private placement units and their constituent securities may expire worthless, except to the extent they receive liquidating distributions from assets outside the trust account, which could create an incentive for our sponsor, executive officers and directors to complete a transaction even if we select an acquisition target that subsequently declines in value and is unprofitable for public”

• Limited investor protections

  “Investors will not be entitled to protections normally afforded to investors in Rule 419 blank check offerings.”